A recent study involving individuals with severe, refractory SLE and multi-organ involvement demonstrated that all three patients treated with CD19-directed CAR-T cells exhibited peak CAR-T expansion by day 14, followed by a contraction phase, accompanied by a pronounced reduction in both the proportion and absolute count of circulating B cells. Here, CD19 is linked to systemic lupus erythematosus.